FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a pharmaceutical composition containing N-[3-chlor-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulphonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine or its pharmaceutically acceptable salt as an active pharmaceutical ingredient in an amount of more than 60 wt % to less than 85 wt % as related to total weight of the composition. The active pharmaceutical ingredient is characterised by a wetting angle of less than 55°.
EFFECT: method for preparing the pharmaceutical composition involves the stage of grinding or milling the above pharmaceutical ingredient in the presence of one or more excipients.
7 cl, 7 dwg, 5 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| CRYSTALLINE γ-MODIFICATION OF N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINOLINE AMINE OF BIS (4-METHYLBENZENESULFONATE) MONOHYDRATE, METHOD OF ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED THEREON | 2016 |
|
RU2603943C1 |
| PELLETISABLE (4'-TRIFLUOROMETHYLPHENYL)AMIDE (Z)-2-CYANO-3-HYDROXY-BUT-2-ENOIC ACID PREPARATION WITH IMPROVED STABILITY | 2010 |
|
RU2681079C2 |
| SOLID DOSAGE FORMS OF PALLBOCYCLOB | 2016 |
|
RU2686840C1 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DORAVIRINE, TENOFOVIR DISOPROXIL FUMARATE AND LAMIVUDINE | 2016 |
|
RU2736941C2 |
| METHOD OF CANCER TREATMENT | 2005 |
|
RU2361589C2 |
| METHOD FOR PREPARING MEDICINAL AGENT CONTAINING VARDENAFIL HYDROCHLORIDE TRIHYDRATE | 2008 |
|
RU2493849C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING PRODRUG OF HCV POLYMERASE INHIBITOR | 2010 |
|
RU2489153C2 |
| PHARMACEUTICAL COMBINATION, COMPOSITION, AND COMBINED FORMULATION CONTAINING A GLUCOKINASE ACTIVATOR AND AN SGLT-2 INHIBITOR, AND METHODS FOR PRODUCTION AND APPLICATION THEREOF | 2019 |
|
RU2770043C1 |
| IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING KETOPROFEN LYSINE SALT | 2019 |
|
RU2804350C2 |
